Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: BDR who wrote (3411)	7/5/1999 9:04:00 AM
From: IRWIN JAMES FRANKEL	Read Replies (1) \| Respond to of 10280

Earnings surprises, smaller losses: Good - Good and Bad Surprises possible - Settle patent dispute on Seldane/Allegra and get royalties - Good. Higher than expected sales of Xopenex - Good. Cut back on R&D expenses - Bad. Either or both of the first two could happen. I do not expect any cutback on development expenses. In fact we seem to be heading for higher expenses. That suits me. I am much more concerned that SEPR build a solid future even at the expense of current earnings. ij